BMS-986141   Click here for help

GtoPdb Ligand ID: 12038

Synonyms: BMS986141 | compound 49 [PMID: 35729784]
Compound class: Synthetic organic
Comment: BMS-986141 is an orally active, selective, and reversible protease-activated receptor 4 (PAR4) antagonist with antiplatelet/antithrombotic activity [1]. It was developed as a back-up to lead compound BMS-986120.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 0
Rotatable bonds 9
Topological polar surface area 160.7
Molecular weight 561.11
XLogP 4.25
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COc1cc(OCc2csc(n2)c2ccc(cc2)C(=O)N(C)C)c2c(c1)oc(c2)c1cn2c(n1)sc(n2)OC
Isomeric SMILES COc1nn2cc(nc2s1)c1cc2c(o1)cc(OC)cc2OCc1csc(n1)c1ccc(cc1)C(=O)N(C)C
InChI InChI=1S/C27H23N5O5S2/c1-31(2)25(33)16-7-5-15(6-8-16)24-28-17(14-38-24)13-36-21-9-18(34-3)10-22-19(21)11-23(37-22)20-12-32-26(29-20)39-27(30-32)35-4/h5-12,14H,13H2,1-4H3
InChI Key KEEBLYWBELVGPQ-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
BMS-986141 is a phase 2 clinical candidate that is designed to reduce the risk of thrombosis in coronary artery disease and stroke.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02671461 Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes" Phase 2 Interventional Bristol-Myers Squibb
NCT05093790 A Study to Evaluate BMS-986141 Added on to Aspirin or Ticagrelor or the Combination, on Thrombus Formation in a Thrombosis Chamber Model in Participants With Stable Coronary Artery Disease and Healthy Participants Phase 2 Interventional Bristol-Myers Squibb